Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's ...
Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual ...
Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, ...
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
In more than 90,000 people across TWO independent cohorts, those with atrial fibrillaion (AF) had a thinner macular ganglion ...
A study published in JAMA Ophthalmology 1 reported that spectacle lenses with highly aspherical lenslets (HAL) are safe and ...
Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina ...
The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...
Rheumatoid arthritis (RA) is an autoimmune disorder that develops much more frequently in women than men, with a ...
Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results